Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib PK in Hepatic Impairment
NCT03282513Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivosidenib in acute myeloid leukemia (AML) and cholangiocarcinoma (CCA) (4 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration and Area under plasma concentration-time curve. Started Sep 2017; status: completed.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03282513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282513.